A portfolio of innovative programs

What we develop

Drug candidates

Sensorion’s mission is to offer innovative therapeutic solutions that provide long-term improvements to the lives of patients suffering from, or at risk of, inner ear disorders. In striving to fill this significant unmet medical and social need, we are continuously developing and optimizing our pipeline, mobilizing our in-house technology platform, scientific expertise, and network of experts.

Program Indication Discovery In vivo POC Pre-clinical Phase 1 Phase 2 Phase 3 Next milestones
RESTORE
OTOF-GT Otoferlin  deficiency 100 90 0 0 0 0 Discussion with reg. authorities – H1 2021
USHER-GT Usher syndrome Type 1 100 10 0 0 0 0 Pre-clinical Confirmatory PoC studies – H1 2021
GJB2-GT GJB2 – related early presbycusis 100 0 0 0 0 0 Candidate selection
GJB2-GT Pediatric progressive GJB2 – related hearing loss 100 0 0 0 0 0 Candidate selection
GJB2-GT Congenital GJB2 – related hearing loss 100 0 0 0 0 0 Candidate selection
TREAT
SENS-401 SSHNL Sudden  sensorineural  hearing loss
(SSNHL)
100 100 100 100 50 0 Phase 2 topline results – Q4 2021
PREVENT
SENS-401 CIO Cisplatin   induced  ototoxicity 100 100 100 90 0 0 Start of natural history clinical study – H1 2021

SENS-401 Cochlear

Hearing  preservation  after cochlear  implantation 100 100 50 0 0 0 Cochlear and Sensorion assessing next steps

SENS-401

Aminoglycoside  induced  ototoxicity 90 0 0 0 0 0

PRODUCTS

Discover all the products

RESTORE

GJB2-GT

Go to the description

RESTORE

USHER-GT

Go to the description

RESTORE

OTOF-GT

Go to the description

PREVENT AND TREAT

SENS-401

Go to the description